Ron is the president and CEO of Albireo Pharma, Inc., a clinical-stage company focused on rare liver disorders. He is also a member of Albireo’s board. As Albireo’s first president and CEO, Ron took the company public in 2016 and advanced a deep pipeline through multiple late-stage clinical trials. Prior to joining Albireo, he spent more than 25 years at Bristol Myers Squibb, working in five different countries and holding positions of increasing responsibility in sales, marketing and general management, culminating in his role as president of Europe, where he was responsible for over 30 countries.
While at BMS, Ron played a leadership role in several product successes, including Abilify®, Avapro®, Atripla®, Eliquis®, Orencia®, Pravachol®, Plavix®, Reyataz®, Sustiva®, Sprycel® and Yervoy®. Ron has successfully completed more than a dozen business development deals. He is a graduate of St. Francis Xavier University in Canada.